Predicting Effective Therapy in Pancreatic Cancer

Memorial Sloan Kettering Cancer Center (MSK) logo

Memorial Sloan Kettering Cancer Center (MSK)

Status

Active, not recruiting

Conditions

Pancreatic Adenocarcinoma
Pancreatic Cancer

Treatments

Diagnostic Test: CTC isolocation and analysis

Study type

Observational

Funder types

Other

Identifiers

NCT03033927
17-042

Details and patient eligibility

About

The purpose of this phase II study is to develop a test to predict response of pancreatic cancer to different chemotherapy regimens.

Enrollment

74 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Histological or cytological diagnosis of pancreatic adenocarcinoma, confirmed at MSKCC, AJCC stage IV disease at time of enrollment.
  • Patient planning to receive treatment with FOLFIRINOX or gem/nab-P chemotherapy, with or without investigational agents.
  • Prior surgery, chemotherapy and/or radiation therapy for AJCC Stage I-III pancreatic adenocarcinoma is permitted.
  • ECOG performance status 0-2.
  • A minimum age of 18 years old.

Exclusion criteria

  • Prior chemotherapy for AJCC stage IV pancreatic adenocarcinoma
  • Known to be HIV positive on antiretroviral therapy
  • Prior organ allograft
  • Any medical or psychiatric condition that may interfere with the ability to comply with protocol procedures

Trial design

74 participants in 1 patient group

Participants with Stage IV Pancreatic Cancer
Treatment:
Diagnostic Test: CTC isolocation and analysis

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems